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Abstract 
Background: Plasmodium falciparum resistance to anti-malarials is a major drawback in effective malaria control 
and elimination globally. Artemisinin-combination therapy (ACT) is currently the key first-line treatment for uncom-
plicated falciparum malaria. Plasmodium falciparum genetic signatures at pfmdr-1, pfcrt, and pfubp-1 loci are known 
to modulate in vivo and in vitro parasite response to ACT. The objective of this study was to assess the distribution 
of these resistance gene markers in isolates collected from different malaria transmission intensity in Ethiopia and 
Tanzania.
Methods: Plasmodium falciparum clinical isolates were collected from different regions of Ethiopia and Tanzania. 
Genetic polymorphisms in the genes pfcrt, pfmdr-1 and pfubp-1 were analysed by PCR and sequencing. Frequen-
cies of the different alleles in the three genes were compared within and between regions, and between the two 
countries.
Results: The majority of the isolates from Ethiopia were mutant for the pfcrt 76 and wild-type for pfmdr-1 86. In con-
trast, the majority of the Tanzanian samples were wild-type for both pfcrt and pfmdr-1 loci. Analysis of a variable linker 
region in pfmdr-1 showed substantial variation in isolates from Tanzania as compared to Ethiopian isolates that had 
minimal variation. Direct sequencing of the pfubp-1 region showed that 92.8% (26/28) of the Ethiopian isolates had 
identical genome sequence with the wild type reference P. falciparum strain 3D7. Of 42 isolates from Tanzania, only 13 
(30.9%) had identical genome sequences with 3D7. In the Tanzanian samples, 10 variant haplotypes were identified.
Conclusion: The majority of Ethiopian isolates carried the main marker for chloroquine (CQ) resistance, while the 
majority of the samples from Tanzania carried markers for CQ susceptibility. Polymorphic genes showed substan-
tially more variation in Tanzanian isolates. The low variability in the polymorphic region of pfmdr-1 in Ethiopia may 
be a consequence of low transmission intensity as compared to high transmission intensity and large variations in 
Tanzania.
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Background
Plasmodium falciparum resistance to anti-malarials 
is a major drawback in effective malaria control in sub-
Saharan Africa. Extensive use of chloroquine (CQ) as a 
monotherapy led to significant increase in levels of resist-
ance across many malaria-endemic countries prompting 
policy changes. Post-CQ and sulfadoxine-pyrimethamine 
(SP) era, artemisinin combination therapy (ACT) such 
as artemether-lumefantrine (AL) has become the most 
important drug for the treatment of uncomplicated fal-
ciparum malaria in many endemic countries [1]. CQ 
resistance in P. falciparum malaria has been associated 
with pfcrt 76T (chloroquine resistance transporter gene) 
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and pfmdr-1 86Y (multidrug resistance gene 1) alleles. 
Artemisinin partner drugs have been documented to 
exert opposing selective pressure on pfcrt and pfmdr-1 
loci in previous studies [2–4]. Mutations in pfmdr-1 play 
a significant role in the parasite’s resistance to a variety 
of anti-malarials including lumefantrine [5, 6]. Indeed, 
the selection of pfmdr-1 86N by AL has been shown 
in a number of studies [7–10]. Likewise, a selection of 
pfcrt K76 was observed in a similar study [3]. Moreover, 
Djimde et  al. [11] showed equal selection of pfcrt 76T 
and pfmdr-1 86Y alleles following artesunate plus amodi-
aquine treatment.
Understanding of the evolution of drug target genes 
under changing drug policy is crucial for drug efficacy 
monitoring using molecular markers [12]. Studies have 
shown that withdrawal of CQ was followed by the expan-
sion of CQ-sensitive parasites possessing a wild type 
pfcrt allele in many countries [8, 13, 14]. The decline in 
CQ resistance after cassation of its use in many endemic 
areas suggests a possible re-introduction of CQ in the 
future [15] for chemoprevention or routine treatment. 
Such a decision requires close regional monitoring 
because evolution of CQ resistance after the removal of 
drug pressure seems to differ considerably among para-
site populations. The fitness deficits incurred by mutant 
pfcrt K76T and pfmdr-1 N86Y strains are different. The 
K76T mutants are more strongly affected by the pres-
ence or absence of drug pressure than the pfmdr-1 N86Y 
mutants. Haplotype “NFD” (N86, 184 F, and D1246) is 
associated with decreased susceptibility to AL and treat-
ment with AL selects for this haplotype [16, 17]. The 
decline in drug resistance after removal of drug pressure 
could provide a new paradigm for anti-malarial treat-
ment policies in Africa and may suggest a possible rota-
tion of CQ in the future [18].
The reduction of malaria-related morbidity and mortal-
ity across sub-Saharan Africa gained in recent years as a 
result of the deployment of ACT, improved vector con-
trol and other measures could be compromised unless 
sustained ACT efficacy is maintained [19, 20]. Thus, the 
emergence of P. falciparum resistance to artemisinin 
derivatives in Greater Mekong sub-region jeopardizes 
these successes [21–23]. A few single nucleotide poly-
morphisms (SNPs) in one or two genes were shown to be 
responsible for resistance to CQ and SP [24]. These SNPs 
were then used as molecular markers to trace retrospec-
tively the path of the resistant parasites. History has 
shown that for both CQ and SP, each resistant parasite 
population was introduced into East Africa from South-
east Asia (SEA) by individuals carrying the resistant 
strain, and then spread throughout the continent [25].
Unfortunately, artemisinin resistant phenotype, typified 
by delayed parasites clearance rates in the first few days 
after ACT treatment, was documented in 2009 in many 
patients from Cambodia [26], the same area where CQ 
and SP resistance started. Mutations in the kelch 13 gene 
have been associated with the slow clearance phenotype 
in Cambodian parasites [27]. This undesirable phenotype 
is steadily widening its territory and has spread across the 
Great Mekong sub-region [23, 28]. The new areas of slow 
parasite clearance would reflect a spread from a focal 
source just analogous to the “old” anti-malarials (CQ and 
SP) although an independent origin of artemisinin resist-
ance has also been noted [29]. However, the variability of 
the K13 gene is low in African isolates and background 
mutations are distinct from the Asian genotypes [30].
The deubiquitinating enzyme gene (pfcubp-1) was first 
identified as a contributor to both CQ and artemisinin 
resistance in Plasmodium chabaudi. Mutations V739F 
and V770F were first identified to confer resistance to 
CQ and artesunate in rodents [31]. Later, pcubp-1 and 
pcap2mu (encoding clathrin vesicle-associated adaptor 2, 
µ subunit) genes were found to confer artemisinin resist-
ance in P. chabaudi [32]. Both these genes are known to 
have polymorphic homologues in P. falciparum. A vari-
ant, E1528D, of the corresponding pfubp-1 was recently 
reported to be associated with reduced susceptibility to 
artemisinin in vitro [33]. Moreover, mutations in both the 
pfubp-1 and the pfap2mu genes have been contributing 
to the genetic signature of persisting sub-microscopic P. 
falciparum in ACT-treated Kenyan children [34]. Signs of 
recent selection of pfubp-1 related to use of artemisinin 
were noted [33] and polymorphisms in this gene may 
be shared determinants associated with slow clearance 
after artesunate monotherapy in Cambodia and Kenya 
[35]. Studies have shown that markers of resistance to 
CQ and amodiaquine (pfmdr-1) are known to be selected 
by ACT toward CQ-sensitive alleles [3, 36] implicated in 
artemisinin resistance. Plasmodium falciparum genome 
exhibits sequence variation that contributes to the path-
ogenic mechanisms of the parasite and determining the 
prevalence of resistance markers could provide a predic-
tion about drug efficacy [37].
Malaria transmission is heterogenous in Ethiopia, rang-
ing from highly seasonal and unstable areas to perennial 
transmission settings. The two major Plasmodium spe-
cies causing malaria in Ethiopia are P. falciparum (about 
60% of cases) and P. vivax (about 40% of cases) [38]. Ethi-
opia replaced CQ with SP as first-line drug for treatment 
of uncomplicated falciparum malaria in 1999, which in 
turn was replaced by AL in 2004, but CQ continues to be 
used for the treatment of P. vivax malaria.
In Tanzania, SP replaced CQ as a first line treatment of 
uncomplicated malaria in August 2001 which in turn was 
replaced by AL as a national first line treatment of uncom-
plicated malaria in 2006 [39]. But CQ is only used under 
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restricted conditions for treatment of malaria in sickle cell 
disease patients. Despite the policy change in Tanzania, 
CQ continued to be available for prophylaxis of malaria in 
sickle cell disease patients. Scanty data are available on the 
effect of ACTs on the selection of molecular markers asso-
ciated with the partner drug of the artemisinin derivative 
in areas with varying malaria transmission and therefore 
different level of drug pressure on the parasite population. 
The purpose of this study was, therefore, to determine 
polymorphisms in pfubp-1, pfcrt and pfmdr-1 genes in 
Ethiopia and Tanzania with AL as the first-line drug for 
uncomplicated falciparum malaria but where Ethiopia 
retained CQ for the treatment of P. vivax malaria.
Methods
Study population and site
In Ethiopia, the study was conducted in three sites (East 
Shoa, Gambella and West Arsi) from October 2012 
through December 2014. East Shoa Zone is located 
99 km from Addis Ababa, Ethiopia. Adama is the admin-
istrative town for the East Shoa Zone. The zone is found 
in the Great Rift Valley depression and malaria transmis-
sion is seasonal and unstable. Malaria transmission usu-
ally starts from September and ends in December. As it is 
true in most parts of Ethiopia, P. falciparum and P. vivax 
co-exist in the study area and malaria transmission is 
usually seasonal and unstable. In many malaria endemic 
areas of Ethiopia, the number of malaria cases substan-
tially decreases (predominantly falciparum malaria cases) 
towards the end of December although vivax cases due 
to relapse appear in all months of the year. From East 
Shoa Zone, samples were collected from Adama malaria 
control centre. Gambella Town is located 777  km from 
Addis Ababa, Ethiopia and is the administrative centre 
of the Gambella Regional State. Gambella is character-
ized by having perennial malaria transmission due to 
uninterrupted suitable climatic conditions. Samples from 
this area were collected from Gambella hospital. West 
Arsi Zone is located 251  km from Addis Ababa, Ethio-
pia. Shashemene is the administrative centre of the West 
Arsi Zone. The zone has elevation ranging from 1,500 to 
2,300 m above sea level. Malaria transmission is seasonal 
and unstable in the West Arsi Zone. Samples from this 
area were collected from Aje Health centre.
The samples in Tanzania were collected from Mkuzi 
in Muheza district, Tanga region, Nachingwea district 
in Lindi, Muleba district in Kagera region and Ilemela 
district in Mwanza region. These sites were selected to 
represent areas with different malaria transmission. The 
sites were selected based on the recent Tanzania HIV and 
malaria indicator survey whereby Nachingwea in Lindi 
have high malaria prevalence while Muleba in Kagera 
have moderate malaria transmission. Muleba is also one 
of the districts which are prone to malaria epidemics in 
the country. The sites, Muheza in Tanga and Ilemela in 
Mwanza have moderate malaria transmission. In all four 
sites, malaria is caused mainly by P. falciparum.
Sample collection
Finger-prick blood samples were collected from patients 
attending clinics/hospitals in the above mentioned study 
sites in Ethiopia and Ilemela, Tanzania after obtaining 
patients’ informed consent. In the other three sites in 
mainland Tanzania, venous blood samples (3–5 ml) were 
collected and all blood samples were spotted on What-
man 3MM filter papers. The papers were first allowed to 
air-dry, the dried blood spots (DBS) were stored in self-
sealing plastic bags for subsequent molecular analysis.
Malaria diagnosis
Thick and thin blood smears stained with 10% Giemsa for 
10 min in all three study sites in Ethiopia. The slides were 
read by two independent experienced lab technicians and 
malaria-infected patients were treated as per the national 
treatment guideline: AL for P. falciparum, CQ for vivax 
malaria. For the three study sites in Tanzania (Mkuzi, 
Nachingwea and Muleba), the slides were stained with 
3% Giemsa for 45  min. Initial screening and treat-
ment of patients were done using RDT and only a sin-
gle microscopy reading was done as a confirmation. For 
determination of parasitaemia, infected red blood cells 
were counted in microscopic fields containing 200 leu-
cocytes and then multiplied by 40 (assuming a standard 
mean white blood cell count of 8,000 leucocytes per μl of 
blood) [40]. A blood smear was considered to be negative 
if no parasite was seen after examining 200 fields.
DNA extraction
Plasmodium falciparum DNA was extracted from DBS 
using the chelex extraction method as described else-
where [41]. DNA obtained was transferred into 0.5  ml 
DNA tubes and kept in −20°C until use.
Genotyping of the pfcrt gene
The pfcrt gene was analysed by PCR–RFLP using prim-
ers flanking residue 76 in two rounds of PCR with two 
pairs of outer and inner primers as described elsewhere 
[42]. The 145-bp nested PCR product was then digested 
with restriction enzyme XapI (Thermo Scientific), which 
cleaves pfcrt-76K but not pfcrt-76T [42, 43]. All PCRs 
were run in a LifePro thermal cycler (Bioer Technology, 
Hangzhou, China).
Genotyping of the pfmdr‑1 gene
The pfmdr-1 was analysed as previously described else-
where [5]. Parasite DNA was amplified with primers 
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flanking codon 86 in two rounds of outer and nested 
PCR using two sets of primers. Pfmdr-1 alleles were 
then identified using ApoI (Thermo Scientific), which 
cleaves the coding sequence of allele pfmdr-1 86N but 
not that of pfmdr-1 86Y. The polymorphic asparagine 
rich linker region was amplified according to Duraisingh 
et  al. [5] and PCR amplicons were analysed by nucleo-
tide sequence determination at Uppsala Genome Centre. 
Sequencing reactions were run with AB BigDye Termi-
nator v3.1 and spin-column based clean-up. Sequencing 
samples were separated by capillary electrophoresis on 
the ABI3730XL DNA Analyzer (Applied Biosystems).
Genotyping of the pfubp‑1 gene
Polymorphisms in pfubp-1 (PF3D7_0104300) in the 
300  bp region encompassing codons 1463–1563 were 
determined using a previously published PCR strat-
egy [33]. The products were characterized by direct 
sequencing.
Statistical analysis
All statistical analyses were performed using STATA 
13.0 (Texas, 77845 USA). The frequency of mutant and 
wild type alleles were calculated as the proportion of all 
the alleles at a given locus detected among all the para-
site isolates examined. The 2-tailed Fisher’s exact test was 
used to compare all isolates from Ethiopia and Tanzania 
at the pfcrt K76T and pfmdr-1 N86Y alleles. Analysis of 
the pfubp-1 region was done by sequence comparison 
with the 3D7 wild type reference P. falciparum strain. 
Statistical significance was defined as a P value ≤0.05.
Ethical considerations
Ethical approval for the study sites in Ethiopia was 
obtained from the Institutional Review Boards of Aklilu 
Lemma Institute of Pathobiology and Science Fac-
ulty, Addis Ababa University and the Armauer Hansen 
Research Institute as well as from the National Health 
Research Ethics Review Committee. For study in 
Mwanza, Tanzania, ethical clearance was obtained from 
Weill Bugando University College of Health Sciences and 
Bugando Medical Centre (WBUCHS/BMC) Ethical and 
Publication Committee. The study conducted at Mkuzi, 
Nachingwea and Muleba received ethical and scientific 
approval from the Medical Research Coordination Com-
mittee (MRCC) of the Tanzanian National Institute for 
Medical Research and the Ministry of Health and Social 
Welfare.
Results
The prevalences of pfcrt 76T and pfmdr1 86Y mutations 
in three study sites in Ethiopia are shown in Table  1. 
Resistance to CQ was essentially fixed in two study sites 
in Ethiopia, West Arsi/Shalla and Adama, with 100% of 
the isolates harboring the pfcrt K76T mutation. In iso-
lates from Gambella, the wild type alleles K76 and N86 
of pfcrt and pfmdr-1 gene were present in 27.3% (6/22) 
and 73.9% (17/23) of the samples, respectively. The prev-
alence of pfmdr-1 86Y mutation was 2% in West Arsi, 
23.3% in Adama and 26.1% in Gambella (Table 1).
In Tanzania, the majority of the isolates carried wild 
type pfcrt 76K and pfmdr-1 86N genes. In two areas of 
Tanzania, Mwanza and Nachingwea, all isolates (100%) 
carried wild type pfcrt 76K gene (Table 1). The prevalence 
of pfcrt 76T mutation was 15 and 14.8% in Mkuzi and 
Muleba, respectively. The frequencies of wild type and 
mutant pfmdr-1 86 in the four study sites in Tanzania are 
shown in Table 1.
An overall comparison of isolates from Ethiopia and 
Tanzania at the pfcrt 76 and pfmdr-1 86 codons showed 
Tanzania to have a significantly higher prevalence of 
the wild type pfcrt 76K allele (91/98; 92.8%) compared 
to Ethiopia (6/152; 4.0%); p  <  0.0001. However, no sig-
nificant difference (p  =  0.4138) was observed between 
Table 1 Frequencies of mutations in pfcrt 76 and pfmdr-1 86 codons in P. falciparum isolates from Ethiopia and Tanzania
Country/locations Pfcrt Pfmdr‑1
76K, n (%) 76T, n (%) Total 86N, n (%) 86Y, n (%) Total
Ethiopia
 Adama 0 (0) 31 (100) 31 23 (76.7) 7 (23.3) 30
 Gambella 6 (27.3) 16 (72.7) 22 17 (73.9) 6 (26.1) 23
 West Arsi 0 (0) 99 (100) 99 49 (98) 1(2) 50
Tanzania
 Muleba 23 (85.2) 4 (14.8) 27 18 (81.8) 4 (18.2) 22
 Nachingwea 31 (100) 0 (0) 31 27 (97.6) 0 (0) 27
 Mwanza 20 (100) 0 (0) 20 7 (87.5) 1 (12.5) 8
 Mkuzi 17 (85.0) 3 (15.0) 20 11 (55.0) 9 (45.0) 20
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isolates the two countries with regard to the pfmdr-1 86 
alleles (63/77; 81.8%, and 89/103; 86.4% wild type in Tan-
zania and Ethiopia, respectively).
Direct sequencing of pfubp-1gene was possible for 42 
Tanzanian and 28 Ethiopian samples (Figure  1). Three 
different types of haplotypes were identified among the 
Ethiopian isolates (one haplotype identical to 3D7, and 
2 other variants). Of 28 Ethiopian isolates, 26 isolates 
(92.8%) had identical genome sequences with 3D7 ref-
erence genome sequence (Figure 2a). There were 11 dif-
ferent types of genome sequences identified among the 
Tanzanian isolates. Of 42 isolates successfully analysed 
from Tanzania, only 13 (30.9%) had identical genome 
sequences with 3D7 (Figure  1). In the Tanzanian sam-
ples, several new variants were found in comparison 
with the earlier published sequence variation [34]. The 
second most common variant, haplotype 2, had a dele-
tion of three amino acids compared to the 3D7 reference 
sequence. Haplotypes 3, 6, 7 and 11 had deletion of one 
glutamic acid, in a part where [34] found insertions of 
one glutamic acid in several isolates. Haplotype 11 had 
in addition the same three amino acid deletion as haplo-
type 2. Finally, haplotype 10 showed a single amino acid 
change from glutamic acid to valine. Haplotypes 4 and 6 
showed a change from glutamic acid to aspartic acid at 
the position indicated earlier [33].
Analysis of the sequence variation in pfmdr-1 variable 
region was possible for a total of 13 isolates from Ethio-
pia and 50 from Tanzania (Figure 2). The variable linker 
region in pfmdr-1 consists of consecutive NDN residues. 
Except for four isolates from Gambella, all isolates from 
Ethiopia had one haplotype sequence, N7D2N9 (Fig-
ure 2a) while the Tanzanian samples had twelve different 
haplotypes (Figure 2b). The dominating variants in Tan-
zania were N7D2N9 and N7D2N10 with almost equal 
frequencies. Representative sequences for all variants 
were deposited at the European Nucleotide Archive with 
accession numbers LN794745-LN794770 (http://www.
ebi.ac.uk/ena/data/view/LN794745-LN794770).
Discussion
Genotyping of pfcrt and pfmdr-1 markers in Ethiopia 
showed distinct frequencies of wild type and mutant 
parasite population. The pfcrt 76T mutation was 100% in 
isolates collected from West Arsi Zone and Adama, cen-
tral Ethiopia. The wild type pfcrt 76K was identified in 
27.3% of the isolates from Gambella, southwestern Ethio-













































*Haplotype identical to the sequence found in the 3D7 reference genome. Nucleotide deletions (haplotypes 3, 6, 7 and 11), amino acid 
change from glutamic acid to valine (haplotype 10) and a change from glutamic acid to aspartic acid at codon 1258, as identified by 
[33] are marked with yellow color.
Figure 1 Haplotype frequencies at codons 1463–1563 of pfubp-1. *Haplotype identical to the sequence found in the 3D7 reference genome. 
Nucleotide deletions (haplotypes 3, 6, 7 and 11), amino acid change from glutamic acid to valine (haplotype 10) and a change from glutamic acid 
to aspartic acid at codon 1258, as identified by [33] are marked with yellow color.
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the parasites from three study sites in Ethiopia were wild 
type. Moreover, analysis of the variable linker region in 
pfmdr-1 showed the presence of one haplotype. Analysis 
of the pfubp-1 region in isolates from Ethiopia showed no 
divergence from the P. falciparum 3D7 reference strain, 
but large variations from 3D7 in Tanzanian isolates.
In the samples collected from two sites in Ethiopia 
(West Arsi and Adama), it has been reported that the 
K76T mutation was present in all isolates examined 
while the wild type amino acid (K) was found in 27.3% of 
samples analysed from Gambella. In all the three study 
sites in Ethiopia, the wild type pfmdr-1 86N dominated 
the parasite population. The variation in the frequencies 
of mutant and wild type in the pfcrt 76 and pfmdr-1 86 
codons could be due to the differential selection of the 
isolates by the current regimen used for the treatment 
of vivax and falciparum malaria in Ethiopia, CQ and AL, 
respectively. The selection of pfmdr-1 86N by AL has 
been shown in a number of studies [1, 8–10, 44]. Under 
CQ pressure, pfcrt 76T alleles spread more rapidly and 
reached high frequencies faster than pfmdr-1 86Y alleles, 
suggesting that CQ selection acts more strongly on pfcrt 
than on pfmdr-1 [44]. The high prevalence of the CQ sen-
sitive pfmdr-1 86N allele signals the survival advantage 
of the wild type over its counterpart mutant forms in the 
currently used AL for falciparum malaria in Ethiopia as 
has been shown the selection of this allele by AL else-
where [9].
Unlike in Ethiopia, the majority of the isolates col-
lected from the four study sites in Tanzania carried the 
wild type alleles for both pfcrt and pfmdr-1. The frequen-
cies of mutant and wild type alleles at pfcrt and pfmdr-1 
loci not only exhibited variation between samples in the 






















Figure 2 Analysis of variation in linker region of pfmdr-1gene among isolates from Ethiopia (a) (n = 28) and Tanzania (b) (n = 66) samples.
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the country. The observed variation in the frequencies 
of mutant and wild type variants for pfcrt and pfmdr-1 
loci in the three study sites in Ethiopia could likely be 
explained by variation in transmission intensities and 
drug pressure per se in each study area. A study in the 
southern and eastern parts of Ethiopia by [45] showed 
the return of wild type alleles for both the pfcrt 76 and 
pfmdr-1 codons. In support of the present findings that 
showed variation in frequencies of mutant and wild type 
variants at pfcrt locus in three study sites in Ethiopia, the 
patchy distribution of pfcrt 76T resistant alleles was also 
seen in Laos, Southeast Asia [46]. Variation in pfmdr-1 
and pfcrt genes among P. falciparum populations in dif-
ferent regions in Sudan, Tanzania and Uganda, and likely 
reflects variation in drug pressure between each region 
[47, 48]. Even under prolonged drug pressure that favors 
resistant parasites to overwhelm, in countries where 
transmission is high and acquired immunity is extensive, 
asymptomatic adults who are less susceptible and who 
generally do not receive therapy, may provide a reservoir 
for susceptible parasites to persist in the population that 
may regain predominance when the pressure is removed 
[14].
The persistence for selection of the mutant genotype, 
pfcrt 76T, in Ethiopia could be attributed to the absence 
of complete CQ withdrawal because studies have shown 
that in areas where drug usage has decreased, the spread 
of resistance has also decreased [15, 49]. To completely 
replace the less-fit CQ resistance genotype, complete with-
drawal of the drug is required [50]. In Uganda, for instance, 
where CQ withdrawal was incomplete, about 8 years post-
CQ replacement pfcrt76T prevalence was between 100 and 
98.7% [37, 51]. In Ethiopia, the at-risk population contin-
ues to inadvertently expose P. falciparum to CQ pressure 
due to CQ-based P. vivax treatment in the country. Within 
8 years of CQ withdrawal in Malawi [15], for instance, the 
prevalence of the chloroquine-resistant pfcrt 76T genotype 
decreased from 85% in 1992 to 13% in 2000. In 2001, CQ 
cleared 100% of 63 asymptomatic P. falciparum infections, 
no isolates were resistant to CQ in vitro, and no infections 
with the CQ-resistant pfcrt76K allele were detected. In 
Cambodia and Thailand, CQ remains the first-line treat-
ment for P. vivax malaria and continues to select for the 
resistant genotype in P. falciparum leading to the fixation 
of pfcrt-K76T alleles [52].
Beyond the pfcrt K76T and pfmdr-1 N86Y alleles, a 
substantial sequence variation in pfmdr-1 variable region 
was noted in isolates from Ethiopia and Tanzania. The 
low variability in the polymorphic region of pfmdr-1 
in Ethiopia may be a consequence of low transmission 
intensity in the country compared to high transmis-
sion intensity in Tanzania. However, it should be noted 
that the majority of the Tanzanian isolates, just like the 
Ethiopian parasites, carried the wild type pfmdr-1 N86 
genotype. The similar prevalence of the pfmdr-1 86N 
allele in both countries could be reflective of its selection 
by AL pressure, since the AL is currently the first-line 
therapy for uncomplicated P. falciparum malaria in both 
countries.
The polymorphism at pfubp-1 codon 1528 previously 
identified in Kenyan samples [33], was not detected in 
Ethiopian samples but was found in two Tanzanian iso-
lates. Overall, nucleotide variability was low in Ethio-
pia and most isolates conformed to the 3D7 reference 
sequence. The variability in Tanzania was strikingly 
larger, and included several new haplotypes not reported 
in an earlier publication [34]. However, because all sam-
ples used in the present study were from patients who 
had been successfully treated with ACT and followed 
only for 3 days after treatment (except samples collected 
from Nachingwea) with no clear signs of slower clear-
ance, it is difficult to make any conclusions with regard 
the possible involvement of this pfubp-1 1528 SNP or the 
new haplotypes in AL response in the study areas under 
report. Further studies with longer follow up would be 
needed to correlate variation in pfubp-1 with increasing 
risk for recrudescence/reinfection.
The pfcrt and pfmdr-1 allele frequencies reported here 
will be useful in the monitoring of rate of reversal of 
resistant forms of these alleles following withdrawal of 
CQ use as a first-line treatment in Ethiopia and Tanzania.
Conclusion
In conclusion, pfcrt 76T mutation was high in Ethiopia 
several years after the change in drug policy unlike other 
studies wherein decline in drug- resistance-associated 
mutations or resistant parasites have been observed. 
Even though CQ is no longer prescribed for uncompli-
cated P. falciparum malaria in Ethiopia, it continues to be 
the standard of care for P. vivax, and this may have led 
to fixation of the CQ-resistant genotype in the study sites 
in Ethiopia. On the other hand, the prevalence of mutant 
pfmdr-1 allele decreased in these samples. In Tanzania, a 
decreased prevalence of pfcrt and pfmdr-1 mutations was 
observed. To better understand the patterns of recovery 
of CQ susceptibility, it is recommend further molecular 
epidemiological studies in different endemic areas hav-
ing different histories of CQ usage. The AL sensitivities 
of isolates with different haplotypes residues in Ethiopia 
and Tanzania need to be determined.
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